Urogen Pharma Ltd

Amid a Stage 2 advancing market with a long-term uptrend, URGN retains a bullish medium-term bias backed by higher-highs/lows and parabolic continuation patterns. However, near-term price is extended and overbought with a bearish exhaustion candle signaling fading upside momentum. A pullback into the rising 9/21 EMA zone offers a higher-odds entry in line with our Speculative strategy’s requirement for clear, asymmetric setups.

• ↑Phase 3 UTOPIA trial shows 94.5% six-month durability for UGN-103
• ↑UGN-102 peak sales forecast >$1B addressing a $5B NMIBC market
• ↓Q1 net loss $23.6 M with operating expenses of $51.5 M